ATE213650T1 - Inklusionskomplexe von radiohalogenierten fettsäuren in einer zyklodextrine - Google Patents

Inklusionskomplexe von radiohalogenierten fettsäuren in einer zyklodextrine

Info

Publication number
ATE213650T1
ATE213650T1 AT95940305T AT95940305T ATE213650T1 AT E213650 T1 ATE213650 T1 AT E213650T1 AT 95940305 T AT95940305 T AT 95940305T AT 95940305 T AT95940305 T AT 95940305T AT E213650 T1 ATE213650 T1 AT E213650T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
fatty acid
pct
date
radio
Prior art date
Application number
AT95940305T
Other languages
English (en)
Inventor
Roberto Pasqualini
Bruno Perly
Laurent Mauclaire
Florence Djedaini-Pilard
Yves Michel
Original Assignee
Cis Bio Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cis Bio Int filed Critical Cis Bio Int
Application granted granted Critical
Publication of ATE213650T1 publication Critical patent/ATE213650T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
AT95940305T 1994-11-14 1995-11-13 Inklusionskomplexe von radiohalogenierten fettsäuren in einer zyklodextrine ATE213650T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413609A FR2726765B1 (fr) 1994-11-14 1994-11-14 Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
PCT/FR1995/001489 WO1996014881A1 (fr) 1994-11-14 1995-11-13 Complexe d'inclusion d'un acide gras radiohalogene dans une cyclodextrine

Publications (1)

Publication Number Publication Date
ATE213650T1 true ATE213650T1 (de) 2002-03-15

Family

ID=9468773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940305T ATE213650T1 (de) 1994-11-14 1995-11-13 Inklusionskomplexe von radiohalogenierten fettsäuren in einer zyklodextrine

Country Status (6)

Country Link
US (1) US5993776A (de)
EP (1) EP0794802B1 (de)
AT (1) ATE213650T1 (de)
DE (1) DE69525647T2 (de)
FR (1) FR2726765B1 (de)
WO (1) WO1996014881A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792942B1 (fr) 1999-04-29 2001-06-08 Commissariat Energie Atomique Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
TWI832684B (zh) 2022-01-27 2024-02-11 美商恩特葛瑞斯股份有限公司 用於儲存分子二硼烷的系統及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508902B1 (fr) * 1981-07-02 1985-09-06 Commissariat Energie Atomique Procede de preparation extemporanee d'un acide gras injectable, marque a l'iode radioactif et preparation de derives iodes utilisables pour la mise en oeuvre de ce procede
EP0153403A4 (de) * 1983-08-17 1985-12-11 Mallinckrodt Inc Chemische verbindungen.
CA1221105A (en) * 1983-09-16 1987-04-28 Alfred H. Dougan Omega halogenated fatty acids
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
US5321014A (en) * 1991-06-28 1994-06-14 The United States Of America As Represented By The Department Of Health And Human Services Molecular encapsulation and delivery of alkenes alkynes and long chain alkanes, to living mammalian cells
US5300280A (en) * 1992-02-14 1994-04-05 Mallinckrodt Medical, Inc. Stabilized radiopharmaceutical kits
JP2715240B2 (ja) * 1993-05-18 1998-02-18 株式会社第一ラジオアイソトープ研究所 放射性ヨウ素標識脂肪酸−シクロデキストリン複合体およびこれを含有するイメージング剤
GB9325330D0 (en) * 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system

Also Published As

Publication number Publication date
WO1996014881A1 (fr) 1996-05-23
DE69525647D1 (de) 2002-04-04
FR2726765A1 (fr) 1996-05-15
EP0794802B1 (de) 2002-02-27
DE69525647T2 (de) 2002-10-17
FR2726765B1 (fr) 1996-12-20
EP0794802A1 (de) 1997-09-17
US5993776A (en) 1999-11-30

Similar Documents

Publication Publication Date Title
DE3783242T2 (de) Aminogruppen enthaltende hochmolekulare verbindungen und deren verwendung.
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
Dahl et al. The structure and distribution of nerves in the pulp-dentin organ
EP0911021A3 (de) Methoden und Zusammensetzungen für feine Linien und/oder Falten
DE69005950D1 (de) Zweiwertige Metallsalze von 2-N,N-di(carboxymethyl)amino,3-cyano,4-carboxymethyl,5-carboxy-thiophensäure, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
DE3789432T2 (de) Hochmolekulare Verbindung, bestehend aus einer Einheit einer zum Asialoglykoproteinakzeptor leitenden Verbindung und aus einer Einheit einer chelatformenden, an dieser chemisch gebundenen, Verbindung, und ihre Verwendung.
DE69126776D1 (de) Parasitizide zusammensetzung und verfahren zu ihrer herstellung und ihre verwendung
ATE187338T1 (de) Zusammensetzung die sowohl eine lösliche als auch eine unlösliche form eines immunogens beinhaltet
NL7705591A (nl) Werkwijze ter bereiding van reukstofcomposities onder toepassing van alifatische 2-methyl-2-al- kyl-alkaanzuuresters alsmede aldus bereide reuk- stofcomposities.
ATE230416T1 (de) Neue mittel zur diagnose von gefässerkrankungen
DE69525647D1 (de) Inklusionskomplexe von radiohalogenierten fettsäuren in einer zyklodextrine
JPS5533497A (en) Silaasubstituted 1*44dihydropyridine derivative
JPH01175924A (ja) 毛髪処理剤
DK293082A (da) Fremgangsmaade til fremstilling af en injicerbar fedtsyre maerket med radioaktivt iod samt iodderivater der kan anvendes ved udoevelse af denne fremgangsmaade
JP2634607B2 (ja) 皮膚外用剤
DE3062300D1 (en) Piperidine derivatives of 4,5-dialkyl-3-hydroxy-pyrrole-2-carboxylic acid esters, their preparation and pharmaceutical compositions containing them
Furseth et al. The fine structure of corticosteroid-covered, human dentine
JPS5536484A (en) Novel 1*44dihydropyridazinee33carboxylic acid derivative
NO168457C (no) Middel til vasking og skylling av haar.
JPH06321812A (ja) 放射性ヨウ素標識脂肪酸−シクロデキストリン複合体およびこれを含有するイメージング剤
DE2606462A1 (de) Arzneimittel zur behandlung von akne vulgaris
JP2000344624A (ja) ステインリムーバー
EP0838215A3 (de) Verwendung von ungesättigten aliphatischen Estern in der Parfümerie
Havránek et al. Biological distribution of99mTc-EDTA derivatives
ATE14727T1 (de) (3,6-pyridazindiylbis(thio))bis-(2,2dimethylalkans|uren) und deren derivate, geeignet als antiarteriosklerotische mittel, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische zusammenstellungen.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties